1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Perrigo Remains Committed To Splitting Off Prescription Despite Delay

 
• By Dave Wallace

Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.

Clock_Nail
Nailing Down Plans To Split Off Perrigo’s Prescription Unit Has Taken Longer Than Expected • Source: Shutterstock

Perrigo insists that it is still committed to plans to split off its Prescription pharmaceuticals business, whether as a sale or a spin-off, despite pushing back such a move while it evaluates timing amid uncertainty and tumult in the US generics market.

“The Rx [Prescription] separation continues to be a strategic priority,” said Perrigo’s president and CEO Murray Kessler, “and we continue to work on effecting a separation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.